Vanda Pharmaceuticals (VNDA) announced that Nereus – tradipitant – is now commercially available across the U.S. for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. Motion sickness affects an estimated 65 to 78 million Americans. The FDA approved Nereus on December 30, 2025, following two pivotal Phase 3 clinical trials. It offers simple dosing with just one or two capsules a day taken approximately an hour before travel.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- AnaptysBio price target lowered to $93 from $95 at Piper Sandler
- VNDA Earnings this Week: How Will it Perform?
- Vanda Pharmaceuticals announces commercial availability for Nereus
- Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
- AnaptysBio price target lowered to $60 from $90 at UBS